Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…
HOME > BUSINESS
BUSINESS
- ViiV Healthcare Files NDA for Triple-Combination HIV Agent in Japan
December 16, 2014
- With Mandatory CDISC-Based Submission Looming, CRO A2 Sees Soaring Orders from Japanese Drug Makers
December 16, 2014
- Sanofi Reiterates Alert on Proper Use of Jevtana; Five Deaths Reported Since Launch in September
December 15, 2014
- Sumitomo Dainippon Aims for NDA Filing for ADHD Treatment Dasotraline in FY2017 in US
December 15, 2014
- Kyowa Kirin Aims to Score Global Sales of 20 Billion Yen for Poteligeo in a Few Years: President Hanai
December 15, 2014
- Astellas Reduces Sales Offices from 159 to 109, Aims to Better Respond to Specific Needs in Each Region: President Hatanaka
December 12, 2014
- Hanshin Dispensing Holding Joins Forces with Convenience Store Lawson
December 12, 2014
- Brexpiprazole Improves Schizophrenia in PIII: Otsuka, Lundbeck
December 11, 2014
- Eisai’s Orexin Receptor Antagonist Improves Sleep Initiation, Maintenance in PII Study
December 11, 2014
- Blopress AG Will Lose Steam after Launch of Rival Generics, Sawai Pres. Predicts
December 11, 2014
- Ono, Kyowa Kirin, BMS to Conduct PI Study of Opdivo and Poteligeo as Combination Therapy in Patients with Solid Tumors
December 11, 2014
- Humanized Bispecific Antibody for Hemophilia A Effective in PI Study: Chugai
December 10, 2014
- Alfresa to Acquire More Shares of Pharmacy Chain Operator
December 10, 2014
- Ethical Drug Sales 1.1%, in October: Crecon Report
December 10, 2014
- Efficacy of Lenalidomide in Treatment-Naïve Patients with Multiple Myeloma Confirmed in Domestic PII Study: Celgene
December 10, 2014
- Takeda, Monash University of Australia to Collaborate in Gastroenterology Field
December 10, 2014
- Data Suggest Potential Feasibility of Ixazomib as Maintenance Therapy for Multiple Myeloma: Takeda
December 9, 2014
- Eisai’s Fycompa Cuts Tonic-Clonic Seizure Frequency by 76.5%
December 9, 2014
- Adcetris Significantly Extends PFS in Post-Transplant Hodgkin lymphoma Patients: Takeda
December 9, 2014
- Abilify Maintena Approved for Use in Acutely Relapsed Adults with Schizophrenia in the US: Otsuka, Lundbeck
December 9, 2014
ページ
Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…